News & Updates
Stay in the Know
Don’t miss the latest news and updates from ELIAS Animal Health
Promising New Data Demonstrates Chemo-Immunotherapy Treatment Approach with ECI® Significantly Improves Outcomes in Dogs with Bone Cancer
LENEXA, Kan. – September 23, 2025 – ELIAS Animal Health, a leader in advancing novel therapies for veterinary cancer care, has published new data from its ASCENT study evaluating a novel chemo-immunotherapy regimen for canine osteosarcoma, an aggressive and often fatal bone cancer in dogs. The analysis was recently presented at the 18th American Association for Cancer Research (AACR) Conference on The Science of Cancer Health Disparities and will be discussed in detail at the upcoming 2025 Veterinary Cancer Society Annual Conference. The ASCENT study investigated a treatment strategy that integrates a single dose of chemotherapy followed by the ELIAS [...]
ELIAS Animal Health to Present New Research at Upcoming Human and Veterinary Oncology Conferences
LENEXA, Kan., September 4, 2025 -- ELIAS Animal Health, a leader in advancing innovative therapies for veterinary oncology, today announced that it will present promising new research on its novel chemo-immunotherapy approach for canine osteosarcoma at two upcoming scientific meetings in September 2025. 18th American Association for Cancer Research (AACR) Conference on The Science of Cancer Health Disparities, being held September 18–21, 2025, in Baltimore, Md. The presentation will highlight the safety and efficacy of integrating traditional cytotoxic chemotherapy with a vaccine-enhanced adoptive cell therapy in canine osteosarcoma, a well-known translational model for pediatric osteosarcoma in humans. 2025 Veterinary Cancer [...]
New Study Data on Chemo-Immunotherapy Approach Using the ELIAS Cancer Immunotherapy (ECI®) to Treat Bone Cancer in Dogs Demonstrates Improved Outcomes
LENEXA, Kan., June 19, 2025 – ELIAS Animal Health, a leading companion animal cancer therapeutics company, today announced interim results from an ongoing clinical study evaluating ELIAS Cancer Immunotherapy (ECI®), a USDA-approved autologous prescription product, combined with chemotherapy for treatment of osteosarcoma, an aggressive form of bone cancer in dogs. The interim analysis, presented at the 2025 American College of Veterinary Internal Medicine (ACVIM) Forum in Louisville, KY, demonstrated that combining the initial cytotoxic effects of chemotherapy with the targeted immune-mediated response stimulated by ECI® has the potential to enhance overall response and survival rates in canine cancer patients. The [...]
Philip J. Bergman, DVM, PhD, DACVIM (Oncology) Joins ELIAS Animal Health Scientific Advisory Board
LENEXA, Kan., April 10, 2025 -- ELIAS Animal Health, a leading innovator in cancer immunotherapies for veterinary medicine, today announced that Dr. Philip J. Bergman, DVM, PhD, DACVIM (Oncology), has joined its Scientific Advisory Board. Philip J. Bergman, DVM, PhD, DACVIM (Oncology) Dr. Bergman brings extensive experience in veterinary oncology, immunotherapy, and translational medicine, with a distinguished career in clinical research and cancer treatment advancements. He has played a pivotal role in pioneering novel cancer therapies for companion animals, including ONCEPT® (a registered trademark of Boehringer Ingelheim Animal Health) which is a fully licensed canine melanoma vaccine, and [...]
ELIAS Animal Health Receives Approval from USDA for the ELIAS Cancer Immunotherapy (ECI®), First-In-Class Treatment for Canine Osteosarcoma
LENEXA, Kan., Mar. 19, 2025 -- ELIAS Animal Health, a leading companion animal cancer therapeutics company, today announced its adoptive cell therapy, ELIAS Cancer Immunotherapy (ECI®), has received approval from the U.S. Department of Agriculture (USDA) Center for Veterinary Biologics (CVB). Cancer is the leading cause of death in dogs over the age of two and represents a significant unmet medical need in veterinary medicine, with an estimated 6 million dogs diagnosed with cancer each year. ECI®, the first autologous prescription product to receive USDA-CVB approval, is indicated for the treatment of canine osteosarcoma, a deadly form of bone cancer. [...]
ELIAS Animal Health Announces Apheresis Partnership with CTAC, Expanding Access to Cancer Immunotherapy in Southeast U.S.
LENEXA, Kan., Feb. 13, 2025 -- In alignment with our commitment to expand access to innovative veterinary cancer care across the country, ELIAS Animal Health is excited to announce that the Canine Transplant and Apheresis Center (CTAC) in Chattanooga, Tennessee is now providing apheresis services to veterinary patients undergoing the ELIAS Cancer Immunotherapy (ECI®). CTAC is located inside the Pullen Cancer Center at VCSG. ECI® is an adoptive cell therapy that harnesses the dog’s own immune system to identify and attack cancer cells. Apheresis is a critical step in the ECI® treatment protocol, which is a one-time procedure used to collect [...]
ELIAS Animal Health Conducting Limb-Sparing Canine Osteosarcoma Clinical Study with Grant from Morris Animal Foundation
LENEXA, Kan., July 31, 2024 /PRNewswire/ -- ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, has initiated a new study evaluating the company’s adoptive T cell therapy—the ELIAS Cancer Immunotherapy (ECI®)—in combination with a novel adjuvant as a limb-sparing treatment for large-breed dogs suffering from appendicular osteosarcoma. The study, which is funded by a grant from Morris Animal Foundation, will be conducted in collaboration with Dr. Jeffrey Bryan and Dr. Megan Mickelson at the University of Missouri. “For dogs with appendicular osteosarcoma, amputation of the affected limb followed by chemotherapy is the [...]
ELIAS Animal Health Expands Manufacturing Capacity Ahead of Product Approval and Pipeline Expansion
OLATHE, Kan., April 30, 2024 /PRNewswire/ -- ELIAS Animal Health, a leading companion animal cancer therapeutics company, is expanding its manufacturing capacity in a larger facility located in Lenexa, Kansas as it prepares for the commercial product launch of the ELIAS Cancer Immunotherapy (ECI®) later this year. In January 2024, ECI® was determined by the USDA as demonstrating a reasonable expectation of efficacy, a significant milestone in the pathway to product licensure, and a significant milestone in veterinary oncology. ECI® is poised to be the only adoptive cell therapy of its kind approved for the treatment of canine osteosarcoma, a [...]